Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL

Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):77-83. doi: 10.1182/hematology.2023000422.ABSTRACTThe tremendous successes of CD19-directed CAR T cells in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) has led to the more widespread use of this important treatment modality. With an ability to induce remission and potentially lead to long-term survival in patients with multiply relapsed/chemotherapy refractory disease, more children are now receiving this therapy with the hope of inducing a long-term durable remission (with or without consolidative hematopoietic cell transplantation). While overcoming the acute toxicities was critical to its broad implementation, the emerging utilization requires close evaluation of subacute and delayed toxicities alongside a consideration of late effects and issues related to survivorship following CAR T cells. In this underexplored area of toxicity monitoring, this article reviews the current state of the art in relationship to delayed toxicities while highlighting areas of future research in the study of late effects in children and young adults receiving CAR T cells.PMID:38066902 | PMC:PMC10727115 | DOI:10.1182/hematology.2023000422
Source: Hematology ASH Education Program - Category: Hematology Authors: Source Type: research